The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 4, 2011, Pages 513-525

  Christensen, Mikkel ^a   Knop, Filip K ^a   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AVE0010; GetGoal; GLP 1; glucagon like peptide 1; glycemic control; lixisenatide; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIXISENATIDE; METFORMIN; PLACEBO; SULFONYLUREA;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 79960159057     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.30     Document Type: Review

References (69)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004). (Pubitemid 38579764)
2. Göke B. Islet cell function: a and b cells - partners towards normoglycaemia. Int. J. Clin. Pract. Suppl. 62(159), 2-7 (2008). (Pubitemid 351229610)
3. Cubbon R, Kahn M, Kearney MT. Secondary prevention of cardiovascular disease in Type 2 diabetes and prediabetes: a cardiologists perspective. Int. J. Clin. Pract. 62(2), 287-299 (2008).
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258), 405-412 (2000). (Pubitemid 30609442)
5. Del Prato S. Megatrials in Type 2 diabetes. From excitement to frustration? Diabetologia 52(7), 1219-1226 (2009).
6. Rosenzweig JL, Ferrannini E, Grundy SM, et al. Primary prevention of cardiovascular disease and Type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(10), 3671-3689 (2008).
7. Gaede P, Lund-Andersen H, Parving H, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358(6), 580-591 (2008). (Pubitemid 351214285)
8. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193-203 (2009).
9. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87(4), 1409-1439 (2007). (Pubitemid 350041474)
10. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80(3), 952-957 (1995).
11. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul. Pept. 85(1), 9-24 (1999). (Pubitemid 29505281)
12. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes 44(9), 1126-1131 (1995).
13. Fehmann HC, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16(3), 390-410 (1995).
14. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet b cells. Diabetes Metab. Res. Rev. 19(2), 115-123 (2003). (Pubitemid 36417195)
15. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48(12), 2358-2366 (1999). (Pubitemid 30395427)
16. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents b cell glucolipotoxicity. Diabetologia 47(5), 806-815 (2004). (Pubitemid 38756992)
17. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol. Scand. 160(4), 413-422 (1997). (Pubitemid 27342031)
18. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101(3), 515-520 (1998). (Pubitemid 28084232)
19. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109(8), 962-965 (2004). (Pubitemid 38282847)
20. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8), 955-961 (2004). (Pubitemid 39128621)
21. Meier JJ, Gethmann A, Götze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49(3), 452-458 (2006). (Pubitemid 43277867)
22. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287(6), E1209-E1215 (2004). (Pubitemid 39491964)
23. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am. J. Physiol. Renal Physiol. 297(6), F1647-F1655 (2009).
24. Li Y, Perry T, Kindy MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl Acad. Sci. USA 106(4), 1285-1290 (2009).
25. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9(9), 1173-1179 (2003). (Pubitemid 37173702)
26. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of Type 2 diabetes mellitus. Drugs 12(8), 503-513 (2009).
27. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J. Pharmacol. Exp. Ther. 307(2), 490-496 (2003). (Pubitemid 37310661)
28. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of Type 2 diabetes. Regul. Pept. 164(2-3), 58-64 (2010).
29. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting b-cells. J. Biol. Chem. 268(26), 19650-19655 (1993). (Pubitemid 23270754)
30. van Eyll B, Lankat-Buttgereit B, Bode HP, Göke R, Göke B. Signal transduction of the GLP-1-receptor cloned from a human insulinoma. FEBS Lett. 348(1), 7-13 (1994). (Pubitemid 24223023)
31. Liu Y, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patient with renal impairment. Presented at: 69th Annual Meeting of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009 (Abstract 557-P).
32. Distiller L, Ruus PE. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in Type 2 diabetes patients. Presented at: 68th Annual Meeting of the American Diabetes Association. San Francisco, CA, USA, 6-8 June 2008 (Abstract 520-P).
33. Becker RHA, Ruus P. Restoration of insulin release with lixisenatide in patients with Type 2 diabetes. Presented at: EASD 46th Annual Meeting, Stockholm, Sweden, 20-24 September 2010.
34. Liu Y, Ruus P. Effect of the GLP-1 agonist AVE0010 on absorption of concomitant oral drugs. Presented at: 69th Annual Meeting of the American Diabetes Association, 5-9 June 2009, New Orleans, LA, USA, (Abstract 495-P).
35. Ratner R, Rosenstock J, Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in Type 2 diabetes insufficiently controlled with metformin. Presented at: 68th Annual Meeting of the American Diabetes Association. San Francisco, CA, USA, 8 June 2008 (Abstract 433-P).
36. Rosenstock J, Ratner R. Post-meal effects of AVE0010, a once-daily GLP-1 receptor agonist, in Type 2 diabetes inadequately controlled on metformin. Presented at: 69th Annual Meeting of the American Diabetes Association. New Orleans, LA, USA, 5-9 June 2009 (Abstract 564-P).
37. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26(3), 881-885 (2003). (Pubitemid 36929359)
38. Gerich JE, Fonseca VA. Monotherapy with GLP-1 receptor agonist, lixisenatide, significantly improves glycaemic control in Type 2 diabetic patients. Presented at: EASD 46th Annual Meeting. Stockholm, Sweden, 20-24 September 2010 (Poster 830).
39. Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res. Clin. Pract. 68(2), 167-175 (2005). (Pubitemid 40602625)
40. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet. Med. 27(9), 1024-1032 (2010).
41. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240-1250 (2008).
42. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39-47 (2009).
43. Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of b-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 23(6), 807-812 (2000). (Pubitemid 30414198)
44. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr. Diab. Rep. 10(2), 124-132 (2010).
45. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 143(8), 559-569 (2005).
46. [No authors listed]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 854-865 (1998).
47. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of Type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53(7), 1258-1269 (2010).
48. Wright EE, Stonehouse AH, Cuddihy RM. In support of an early polypharmacy approach to the treatment of Type 2 diabetes. Diabetes Obes. Metab. 12(11), 929-940 (2010).
49. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with Type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc. Diabetol. 9, 6 (2010).
50. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701), 1606-1616 (2009).
51. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33(6), 1173-1175 (2010).
52. Kielgast U, Holst JJ, Madsbad S. Treatment of Type 1 diabetic patients with residual b cell function with the once-daily glucagon-like peptide-1 analogue liraglutide. Presented at: 46th EASD Annual Meeting. Stockholm, Sweden, 21 September 2010.
53. NIH ClinicalTrials.gov http://clinicaltrials.gov
54. European Medicines Agency. European Public Assessment Reports - Byetta www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/000698/ human-med-000682. jsp&murl=menus/medicines/medicines. jsp&mid= WC0b01ac058001d125
55. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy www.clinicaltrials.gov/ct2/results?term=00688701
56. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea www.clinicaltrials.gov/ct2/results?term=00866658
57. ClinicalTrials.gov: GLP-1 Agonist AVE0010 Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin www.clinicaltrials.gov/ct2/results?term=00707031
58. ClinicalTrials.gov: GLP-1 Agonist AVE0010 (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin www.clinicaltrials.gov/ct2/results?term=00712673
59. ClinicalTrials.gov: Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin www.clinicaltrials.gov/ct2/results?term=01169779
60. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin www.clinicaltrials.gov/ct2/results?term=00763451
61. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea www.clinicaltrials.gov/ct2/results?term=00713830
62. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GetGoal-MONO Japan LTS) www.clinicaltrials.gov/ct2/results?term=00905255
63. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone www.clinicaltrials.gov/ct2/results?term=00763815
64. ClinicalTrials.gov: GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin www.clinicaltrials.gov/ct2/results?term=00715624
65. ClinicalTrials.gov: Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) www.clinicaltrials.gov/ct2/results?term=01147250
66. ClinicalTrials.gov: 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 www.clinicaltrials.gov/ct2/results?term=00976937
67. ClinicalTrials.gov: Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes www.clinicaltrials.gov/ct2/results?term=01175473
68. ClinicalTrials.gov: Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1 www.clinicaltrials.gov/ct2/results?term=01146678
69. ClinicalTrials.gov: 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine www.clinicaltrials.gov/ct2/results?term=00975286